Home Newsfeeds Evercore ISI Group Maintains Outperform on Meta Platforms, Raises Price Target to $275

Evercore ISI Group Maintains Outperform on Meta Platforms, Raises Price Target to $275

Evercore ISI Group analyst Mark Mahaney maintains Meta Platforms (NASDAQ:META) with a Outperform and raises the price target from $170 to $275.

byBenzinga Newsdesk

February 2, 2023

1 minute read

Evercore ISI Group analyst Mark Mahaney maintains Meta Platforms (NASDAQ:META) with a Outperform and raises the price target from $170 to $275.

Walmart Is Pushing The Singing Machine Stock Higher Today: What’s Going On?

By Adam Eckert

July 18, 10:43 AM

The Singing Machine Company Inc (NASDAQ: MICS) shares are trading higher Tuesday after the company launched a new party accessory line available at Walmart.

MICS

BlackRock Plans To Add Proxy Voting Choice To Its Largest ETF

By Akanksha Bakshi

July 17, 9:01 AM

BlackRock Inc (NYSE: BLK) plans to expand its Voting Choice program to its largest ETF – the iShares Core S&P 500 ETF (IVV) with $305 billion in assets under management (AUM), subject to iShares Board approval.

BLK

B. Riley Financial Forecasts Lower Operating Adjusted EBITDA For FY22

By Shivani Kumaresan

December 27, 10:06 AM

B. Riley Financial Inc (NASDAQ:RILY) said it expects fourth-quarter FY2022 operating adjusted EBITDA of $90 million – $100 million. For FY22,…

RILY

Analyst Ratings

HC Wainwright & Co. Maintains Buy Rating for Celldex Therapeutics: Here’s What You Need To Know

By Benzinga Insights

July 1, 12:08 PM

HC Wainwright & Co. has decided to maintain its Buy rating of Celldex Therapeutics (NASDAQ:CLDX) and raise its price target from $60.00 to $73.00. Shares of Celldex Therapeutics are trading down 14.91% over the last 24 hours, at $22.94 per share.

CLDX

Evercore ISI Group Maintains Outperform on Meta Platforms, Raises Price Target to $275

Related Posts

Walmart Is Pushing The Singing Machine Stock Higher Today: What’s Going On?

BlackRock Plans To Add Proxy Voting Choice To Its Largest ETF

B. Riley Financial Forecasts Lower Operating Adjusted EBITDA For FY22

HC Wainwright & Co. Maintains Buy Rating for Celldex Therapeutics: Here’s What You Need To Know